The U.S. government, which developed and patented the use of Truvada for PrEP, got nothing.
The maker of Truvada enjoyed profit in the billions from sales of the only drug approved for HIV prevention, or pre-exposure prophylaxis (PrEP), in the U.S.
A report in The Washington Post details that the federal government issued $50 million in grants to researchers developing PrEP. Read More
